Cell therapy weekly: US FDA grants priority review to cilta-cel CAR-T therapy for multiple myeloma

This week: the US FDA has granted a priority review to ciltacabtagene autoleucel (cilta-cel) – a BCMA-directed CAR-T therapy – for adult patients with multiple myeloma; BlueRock Therapeutics and Senti Bio enter a collaboration to develop gene circuit-engineered cell therapies for regenerative medicine; and Mustang Bio has reported that the first patient has been dosed with their autologous CAR-T therapy – MB-101 – in a Phase I trial for leptomeningeal brain tumors. The news highlights: US FDA grants priority review to cilta-cel CAR-T therapy for multiple myeloma Collaboration to develop gene circuit-engineered cell therapies for regenerative medicine First patient dosed...